109 related articles for article (PubMed ID: 7078806)
1. [Myocardial disease caused by adriamycin. Experimental animal models and possible pharmacologic prevention].
Decorti G; Bartoli Klugmann F; Klugmann S
Minerva Med; 1982 May; 73(19):1275-82. PubMed ID: 7078806
[TBL] [Abstract][Full Text] [Related]
2. [Chronic toxicities of adriamycin (ADR) and their possible prevention by coenzyme Q10 and verapamil in rabbits--especially ADR induced cardiomyopathy (author's transl)].
Dohmae N; Sawada H; Tashima M; Uchino H; Matsuyama E; Konishi T
Nihon Gan Chiryo Gakkai Shi; 1979 Oct; 14(6):1009-28. PubMed ID: 541529
[No Abstract] [Full Text] [Related]
3. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
4. Protection from adriamycin-induced cardiomyopathy in rats.
Shug AL
Z Kardiol; 1987; 76 Suppl 5():46-52. PubMed ID: 3433883
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
Outomuro D; Grana DR; Azzato F; Milei J
Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
[TBL] [Abstract][Full Text] [Related]
6. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
7. Effects of L-carnitine on adriamycin-induced cardiomyopathy in rabbit.
Paterna S; Furitano G; Scaffidi L; Barbarino C; Campisi D; Parisi G; Carreca I
Int J Tissue React; 1984; 6(1):91-5. PubMed ID: 6715123
[TBL] [Abstract][Full Text] [Related]
8. Effects of pyrrolidine dithiocarbamate on antioxidant enzymes in cardiomyopathy induced by adriamycin in rats.
Mingyan E; Hongli L; Shufeng L; Bo Y
Cardiology; 2008; 111(2):119-25. PubMed ID: 18376123
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
10. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Herman EH; Ferrans VJ
Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
[TBL] [Abstract][Full Text] [Related]
11. Experimental animal models of adriamycin cardiotoxicity.
Doroshow JH; Locker GY; Myers CE
Cancer Treat Rep; 1979 May; 63(5):855-60. PubMed ID: 110445
[TBL] [Abstract][Full Text] [Related]
12. Failure of carnitine to prevent adriamycin cardiomyopathy.
Goldsmith MA; Suzuki Y; Ohnuma T; Holland JF
Cancer Treat Rep; 1979 Apr; 63(4):558-60. PubMed ID: 445512
[No Abstract] [Full Text] [Related]
13. Verapamil in the prevention of adriamycin-induced cardiomyopathy.
Garbrecht M; Müllerleile U
Klin Wochenschr; 1986; 64 Suppl 7():132-4. PubMed ID: 3560773
[No Abstract] [Full Text] [Related]
14. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit.
Jaenke RS
Cancer Res; 1976 Aug; 36(8):2958-66. PubMed ID: 1277204
[TBL] [Abstract][Full Text] [Related]
15. Dietary fish oil does not prevent doxorubicin-induced cardiomyopathy in rats.
Matsui H; Morishima I; Hayashi K; Kamiya H; Saburi Y; Okumura K
Can J Cardiol; 2002 Mar; 18(3):279-86. PubMed ID: 11907617
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-induced cardiomyopathy.
Muggia FM; Speyer JL
N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
[No Abstract] [Full Text] [Related]
17. Doxorubicin (adriamycin) cardiomyopathy.
Saltiel E; McGuire W
West J Med; 1983 Sep; 139(3):332-41. PubMed ID: 6356608
[TBL] [Abstract][Full Text] [Related]
18. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
19. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
20. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
